SCHEMBL3894798

SCHEMBL3894798

CCOc1cc(C(C)NCCc2cccs2)ccc1Oc1ccc(C(N)=O)cn1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 5/20 0.39
ALDH1A1 P00352 5/20 0.39
RAB9A P51151 5/20 0.39
SMN1; SMN2 Q16637 4/20 0.39
HPGD P15428 2/20 0.39
CYP1A2 P05177 1/20 0.39
CYP2D6 P10635 1/20 0.39
CYP2C9 P11712 1/20 0.39
CYP2C19 P33261 1/20 0.39
OPRM1 P35372 6/20 0.38
OPRD1 P41143 6/20 0.38
OPRK1 P41145 6/20 0.38
KDM4E B2RXH2 2/20 0.38
MAPT P10636 2/20 0.37
GRIN2D O15399 1/20 0.37
GRIN3B O60391 1/20 0.37
SLC6A2 P23975 1/20 0.37
SLC6A3 Q01959 1/20 0.37
GRIN1 Q05586 1/20 0.37
KCNH2 Q12809 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13773076 0.85 OPRM1 (0.52) NPC1ALDH1A1RAB9ASMN1; SMN2OPRM1
SCHEMBL3894795 0.84 OPRM1 (0.52) NPC1ALDH1A1RAB9ASMN1; SMN2HPGD
SCHEMBL3774236 0.84 OPRM1 (0.52) ALDH1A1SMN1; SMN2CYP1A2CYP2D6CYP2C9
SCHEMBL3705210 0.76 CYP2C19 (0.54) ALDH1A1CYP1A2CYP2D6CYP2C9CYP2C19
SCHEMBL13285437 0.75 OPRM1 (0.53) NPC1ALDH1A1RAB9ASMN1; SMN2CYP1A2
SCHEMBL3695624 0.74 OPRM1 (0.55) NPC1ALDH1A1RAB9ASMN1; SMN2OPRM1
SCHEMBL3691002 0.74 OPRM1 (0.59) OPRM1OPRD1OPRK1GRIN2DGRIN3B
SCHEMBL3692802 0.73 OPRM1 (0.53) NPC1ALDH1A1RAB9ACYP1A2CYP2D6
SCHEMBL13285562 0.72 CYP2D6 (0.49) ALDH1A1CYP1A2CYP2D6CYP2C9CYP2C19
Hydrochloric Acid SCHEMBL3773058 0.72 CYP1A2 (0.51) ALDH1A1CYP1A2CYP2D6CYP2C19OPRM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7560463-B2 Diaryl ethers as opioid receptor antagonists ELI LILLY AND COMPANY (US) 2009-07-14 US disclosed
US-7531557-B2 Diaryl ethers as opioid receptor antagonists ELI LILLY AND COMPANY (US) 2009-05-12 US disclosed
US-20080269296-A1 DIARYL ETHERS AS OPIOID RECEPTOR ANTAGONISTS BLANCO-PILLADO MARIA-JESUS 2008-10-30 US disclosed
US-20080255152-A1 DIARYL ETHERS AS OPIOID RECEPTOR ANTAGONISTS ELI LILLY AND COMPANY 2008-10-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080269296-A1 DIARYL ETHERS AS OPIOID RECEPTOR ANTAGONISTS OPRM1, OPRD1, OPRL1 NPC1 1776/4885ALDH1A1 2083/4885RAB9A 939/4885
US-20080255152-A1 DIARYL ETHERS AS OPIOID RECEPTOR ANTAGONISTS OPRM1, OPRD1, OPRL1 NPC1 1797/4885ALDH1A1 2104/4885RAB9A 943/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.